Adherence to antiretroviral therapy in Nigeria: An overview of research studies and implications for policy and practice

HIV/AIDS - Research and Palliative Care

Volumn 2, Issue , 2010, Pages 69-76

  Monjok, Emmanuel ^a   Smesny, Andrea ^a   Okokon, Ita B ^b   Mgbere, Osaro ^c   Essien, E James ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF CALABAR   (Nigeria)

^c Bureau of Epidemiology   (United States)

Author keywords

Adherence; Antiretroviral therapy (ART); HIV; Nigeria; PLWHA

Indexed keywords

EID: 77954543750     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. UNAIDS. Report on the global HIV/AIDS epidemic 2008. Geneva Switzerland: UNAIDS: 2008.
2. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
3. Peterson GL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcome in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
4. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19:1243-1249.
5. Chesney MA. The elusive gold standard: future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S3-S9.
6. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
7. Bangsberg DR, Acoata EP, Gupta R, et al. Adherence-resistance relationships for protease and nonnucleoside reverse transcriptase inhibitors explained by virologic fitness. AIDS. 2006;20:223-231.
8. Bangsberg DR, Perry S, Charlebios ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
9. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African Adults. J Acqui Immune Defic Syndr. 2006;43:78-84.
10. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-1058.
11. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA. 2006;296(6):679-690.
12. Mills EJ, Nachega JB, Bangsberg DR, Sing S, Rachlis B, et al. Adherence to HAART: A systemic review of developed and develop- ing nation patient-reported barriers and facilitators. PLoS Med. 2006; 3(11):e438.
13. Castro A. Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Med. 2005;2(12):e338.
14. Idigbe EO, Adewole TA, Eisen G, et al. Management of HIV-1 infection with combination of Nevirapine, Stavudine, and Lamivudine; a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr. 2005;40(1):65-69.
15. Lambo E. Nigeria has established 74 ARV treatment centers nationwide. HIV/AIDS News. 2006 March 15.
16. WHO. World Health Statistics 2007. Geneva, Switzerland: World Health Organization; 2007.
17. Daniel OJ, Oladapo OT, Ogundahunsi OA, Fagbenro S, Ogun SA, Odusoga OA. Default from antiretroviral treatment program in Sagamu, Nigeria. Afr J Biomed Res. 2008;11:221-224.
18. Erah PO, Arute JE. Adherence of HIV/AIDS patients to antiretroviral therapy in a tertiary health facility in Benin City. Afr J Pharm Phar- macol. 2008;2(7):145-152.
19. Idoko JA, Agbaji O, Agaba P, et al. Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective. Int J STD AIDS. 2007;18:760-763.
20. Afolabi MO, Ijadunola KT, Fatusi AO, Olasode OA. Determinants of adherence to antiretroviral drugs among people living with HIV/AIDS in the Ife-Ijesa of Osun State, Nigeria. Afr J Prm Health Care Fam Med. 2009:1(1), Art # 6, 6 pages. DOI:10.4102/phcfm.v1i1.6.
21. Nwauche CA, Erhabor O, Ejele OA, Akani CI. Adherence to antiretroviral therapy among HIV-infected subjects in a resource- limited setting in the Niger Delta of Nigeria. Afr J Health Sci. 2006;13(3-4):13-17.
22. Habib AG, Shepherd JC, Eng MLK, et al. Adherence to antiretroviral therapy(ART) during Muslim Ramadan fasting. AIDS Behav. 2009;13:42-45.
23. Olowookere SA, Fatiregun AA, Akinyemi JO, Bamgboye AE, Osagbemi GK. Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. J Infect Dev Ctries. 2008;2(5): 369-372.
24. Mukhtar-Yola M, Adeleke S, Gwarzo D, Ladan ZF. Preliminary investigation of adherence to antiretroviral therapy among chil- dren in Aminu Kano Teaching Hospital, Nigeria. Afr J AIDS Res. 2006;5(2):141-144.
25. Uzochukwu BSC, Onwujekwe OE, Onoka AC, Okoli C, Uguru NP, Chukwuogo OI. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009;24:189-196.
26. Shaahu VN, Lawoyin TO, Sangowawa AO. Adherence to highly active antiretroviral therapy (HAART) at a Federal Medical Center. Afr J Med Sci. 2008;37:29-36.
27. Iliyasu IS, Kabir M, Abubakar IS, Babashani M, Zubair ZA. Compliance to antiretroviral therapy among AIDS patients in Amino Kano Teaxhing Hospital, Kano, Nigeria. Nig J Med. 2005;14(3):290-294.
28. Mohammed MD, Sarki R. Adherence to antiretroviral drugs in North- Central zone of Nigeria. East and Central African Journal of Pharma- ceutical Sciences. 2004;7(3):52-55.
29. Nachega JB, Mill EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 2010;5(1)70-77.
30. Ware NC, Idoko J, Kanya S, et al. Explaining adherence success in subSaharan Africa: an ethnographic study. PLoS Med. 2009;6(1):e1000011.
31. Culbert H, Tu D, O'Brian DP, et al. HIV treatment in a conflict setting: outcome and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med. 2007;4:e129.
32. Ellman T, Culbert H, Torres-Feced V. Treatment of AIDS in conflict affected settings: a failure of imagination. Lancet. 2006;365:278-280.
33. Valdiseri OR. HIV/AIDS stigma: An impediment to public health. Am J Public Health. 2000;92(3):341-342.
34. Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Soc Sci Med. 2003;57:13-24.
35. UNAID 2008: Report on the global AIDS epidemic: Geneva: UNAIDS 2008. Available from http://www.unaids.org/en/KnowledgeCentre/HIV-Data/GlobalReport/2008/. Accessed Nov 20, 2009.
36. Farmers P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Org. 2001;79:1145-1151.
37. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDS. 2002;16:527-535.
38. Nachega JB, Chaisson RE, Goliath RE, et al. Randomized control trial of trained patient-nominated treatment supporters providing directly observed antiretroviral therapy in HIV infected adults: 16th Conference on Retroviruses and Opportunistic Infections: 2009 Feb 8-11, Montreal, Canada. Abstract no. 143.
39. Wohl AR, Garland WH, Valencia R, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis. 2006;42:1628-1635.
40. Gross R, Tierney C, Andrade A, et al; AIDS Clinical Trial Group A5073 Study Team. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naïve HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009;169:1224-1232.
41. Ekong E, Akinlade O, Uwah A, Grant-Isibor I. Study of determinants of non-adherence to antiretroviral drug therapy in a resource-limited setting: 9th European AIDS Conference(EACS): 1st EACS resistance and pharmacology workshop: 2003 Oct 25-59, Warsaw, Poland.